Finanzen von Traws Pharma Inc (TRAW)TRAWTraws Pharma Inc

Traws Pharma Inc (TRAW) generates its revenue primarily from Symbio, which accounts for 100.0% of total sales, equivalent to $2.73M. Understanding this concentration is critical for investors evaluating how TRAW navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Traws Pharma Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -330.37%, provide a clear picture of how effectively TRAW converts its operational activities into shareholder value.

In the context of the broader market, TRAW competes directly with industry leaders such as HLSQ and CVKD. With a market capitalization of $3.49M, it holds a significant position in the sector. When comparing efficiency, TRAW's gross margin of N/A stands against HLSQ's 29.22% and CVKD's N/A. Such benchmarking helps identify whether Traws Pharma Inc is trading at a premium or discount relative to its financial performance.

Traws Pharma has shown erratic financial performance with total revenues peaking at $2,733,000 in Q2 2025 but dropping to $0 in subsequent quarters. The net income has been negative for the last several quarters, with a net loss of $5,691,000 in Q1 2026 and $2,611,000 in Q2 2026.